Voriconazole dosing in children younger than 3 years undergoing cancer chemotherapy or hematopoietic stem cell transplantation

Shirley Qiong Yan, Brian Seyboth, Rachel Kobos, Anne Eaton, Susan K. Seo, Nina Cohen

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


There are limited pediatric population pharmacokinetic data for voriconazole dosing, particularly in younger children. In a cohort of 34 patients younger than 3 years receiving voriconazole, the majority (n = 23, 68%) had a low initial serum concentration <1 mg/L. Among 23 children <2 years old, 19 (83%) had an initial trough <1 mg/L. There was large intra- and interindividual variability in trough levels. Dosing also varied from 3.3 to 19.6 mg/kg per dose. Only 2 of 34 patients had a documented adverse drug reaction attributable to voriconazole. More data are needed to establish optimal dosing in very young children.

Original languageEnglish (US)
Pages (from-to)169-171
Number of pages3
JournalJournal of the Pediatric Infectious Diseases Society
Issue number2
StatePublished - May 15 2018
Externally publishedYes

Bibliographical note

Funding Information:
Financial support. This work was funded in part through the National Institutes of Health/National Cancer Institute Cancer Center Support Grant P30 CA008748. Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Publisher Copyright:
© The Author(s) 2018. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved.


  • Children
  • Oncology
  • Pharmacokinetics
  • Voriconazole


Dive into the research topics of 'Voriconazole dosing in children younger than 3 years undergoing cancer chemotherapy or hematopoietic stem cell transplantation'. Together they form a unique fingerprint.

Cite this